Chiari Francesco, Guarino Pierre, Caporale Claudio Donadio, Orsini Klizia, Trevisi Gianluca, Presutti Livio, Molteni Gabriele
Otolaryngology and Audiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Otolaryngology Head and Neck Unit, "Santo Spirito" Hospital, Pescara, Italy.
Eur Arch Otorhinolaryngol. 2025 Feb;282(2):611-622. doi: 10.1007/s00405-024-08957-7. Epub 2024 Sep 5.
Draf III procedure is a challenging endoscopic technique, which has gradually gained an increasing popularity in treating frontal sinus pathologies. The main aim of this systematic review is to offer a comprehensive overview on clinical indications, pre-operative evaluation, surgical techniques, post-operative management and complications of the Draf III procedure. As a step forward, such issues have been comparatively evaluated as referred to patients who underwent primary Draf III procedure and revision DRAF III one). Finally, surgical outcomes related to mucosal flaps and stents to prevent re-stenosis are analyzed.
A systematic literature review has been performed following PRISMA 2020 checklist statement. An automated search has been carried out by applying an extensive set of queries on the Embase/PubMed, Scopus and Cochrane databases, relating to papers published from 2000 to 2021.
Frontal chronic refractory sinusitis is the most frequent indication to Draf III procedure (72%), followed by mucoceles (11%) and skull base or paranasal tumors (10%). The success rate of primary and revision Draf III are 83.5% and 71%, respectively. The re-stenosis phenomenon seems to depend on allergic mechanism and polyposis). The use of mucosal flaps could improve the Draf III efficacy, better than the use of stents (87 vs 72% of neo-ostium patency).
Draf III is a safe and highly effective surgical technique. However, some limited clinical conditions require some careful technical features, such as the use of mucosal flap, in order to prevent re-stenosis.
Draf III手术是一项具有挑战性的内镜技术,在治疗额窦病变方面逐渐受到越来越多的关注。本系统评价的主要目的是全面概述Draf III手术的临床适应证、术前评估、手术技术、术后管理及并发症。进一步地,对接受初次Draf III手术和Draf III翻修手术的患者的上述问题进行了比较评估。最后,分析了与预防再狭窄的黏膜瓣和支架相关的手术效果。
按照PRISMA 2020清单声明进行系统的文献综述。通过在Embase/PubMed、Scopus和Cochrane数据库上应用大量查询,对2000年至2021年发表的论文进行自动检索。
慢性难治性额窦炎是Draf III手术最常见的适应证(72%),其次是黏液囊肿(11%)和颅底或鼻旁肿瘤(10%)。初次和翻修Draf III手术的成功率分别为83.5%和71%。再狭窄现象似乎取决于过敏机制和息肉病。使用黏膜瓣比使用支架能更好地提高Draf III手术的疗效(新造口通畅率分别为87%和72%)。
Draf III是一种安全且高效的手术技术。然而,一些有限的临床情况需要一些谨慎的技术特点,如使用黏膜瓣,以防止再狭窄。